Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: The state of the art

Current Oncology

Volumn 19, Issue 5, 2012, Pages 259-268

  Clemons, M ^a   Gelmon, K A ^b   Pritchard, K I ^c   Paterson, Alexander H G ^d  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Denosumab; Skeletal related events

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADVANCED CANCER; ANTIGEN BINDING; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MYALGIA; NAUSEA; NEPHROTOXICITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; PATHOPHYSIOLOGY; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84867054608     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1011     Document Type: Review

References (52)

1. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7.
2. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-76.
4. van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (apd) treatment. Lancet 1987;2:983-5.
5. LoRusso P. Analysis of skeletal related events in breast cancer and response to therapy. Semin Oncol 2001;28(suppl 11):22-7.
6. Costa L, Badia X, Chow E, Lipton A, Wardley A. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008;16:879-89.
7. Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 2009;6:163-74.
8. Jensen AØ, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT. Incidence of bone metastases and skeletalrelated events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 2011;11:29.
9. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer 2000;88:1082-90.
10. Van Poznak C. Predicting skeletal complications in metastatic breast cancer raises challenges. Breast Cancer Res Treat 2010;123:781-3.
11. Trinkaus M, Simmons C, Myers J, Dranatisaris G, Clemons M. Skeletal-related events (sres) in breast cancer patients with bone metastases treated in the nontrial setting. Support Care Cancer 2010;18:197-203.
12. Brown JE, Cook RJ, Lipton A, Costa L, Coleman RE. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 2010;123:767-79.
13. Clemons M, Cole DE, Gainford MC. Can bone markers guide more effective treatment of bone metastases from breast cancer? Breast Cancer Res Treat 2006;97:81-90.
14. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase iii, double-blind, comparative trial. Cancer J 2001;7:377-87.
15. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008;113:193-201.
16. Käkönen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003;97(suppl 3):834-9.
17. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
18. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
19. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int 2008;19:733-59.
20. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
21. Tubiana-Hulin M, Beuzeboc P, Mauriac L, et al. Doubleblinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases [French]. Bull Cancer 2001;88:701-7.
22. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, Protocol 19, Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44.
23. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54.
24. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer 2003;98:1735-44.
25. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002;20(suppl 2):45-54.
26. Heras P, Kritikos K, Hatzopoulos A, Georgopoulou AP. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. Eur J Cancer Care (Engl) 2009;18:653-6.
27. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase iii studies. Br J Cancer 2004;90:1133-7.
28. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;(3):CD003474.
29. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumorinduced bone disease. Nat Clin Pract Oncol 2007;4:42-55.
30. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-32.
31. Novartis Pharmaceuticals Canada. Zometa (Zoledronic Acid) [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada; 2009.
32. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011;29:1221-7.
33. Bayer Inc. Bonefos (Clodronate Disodium) [product monograph]. Toronto, ON: Bayer Inc.; 2010.
34. Novartis Pharmaceuticals Canada. Aredia (Pamidronate Disodium) [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada; 2009.
35. Novartis Pharmaceuticals Canada. Aclasta (Zoledronic Acid) [product monograph]. Dorval, QC: Novartis Pharmaceuticals Canada; 2009.
36. Olson K, Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007;13:223-9.
37. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009;67(suppl 5):2-12.
38. Gebara SN, Moubayed H. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. Am J Health Syst Pharm 2009;66:1541-7.
39. European Medicines Agency (emea). CHMP Assessment Report on Bisphosphonates and Osteonecrosis of the Jaw. London, U.K.: emea; 2009. [Available online at: http://www.ema. europa.eu/docs/en_GB/document_library/Report/2010/01/ WC500051428.pdf; cited May 18, 2011]
40. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20:137-45.
41. Amgen Canada. Xgeva (Denosumab) [product monograph]. Mississauga, ON: Amgen Canada; 2011.
42. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, doubleblind study. J Clin Oncol 2010;28:5132-9.
43. Stopeck A, Fallowfield L, Patrick D, et al. Effects of denosumab versus zoledronic acid (za) on pain in patients (pts) with metastatic breast cancer: results from a phase iii clinical trial [abstract 1024]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ascov2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=74&abstract ID=44468; cited July 17, 2012]
44. Fallowfield L, Patrick D, Body J, et al. Effects of denosumab versus zoledronic acid (za) on health-related quality of life (hrql) in metastatic breast cancer: results from a randomized phase iii trial [abstract 1025]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=74&abstract ID=49593; cited July 17, 2012]
45. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study. Lancet 2011;377:813-22.
46. Verma S, Kerr-Cresswell D, Dranitsaris G, et al. Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian medical oncologists. Support Care Cancer 2004;12:852-8.
47. Fornier MN. Denosumab: second chapter in controlling bone metastases or a new book? J Clin Oncol 2010;28:5127-31.
48. Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer 2011;19:1687-96.
49. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase ii trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006;24:4895-900.
50. Fizazi K, Lipton A, Mariette X, et al. Randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-71.
51. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007;12:1035-43.
52. Saad F, Lipton A. Src kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177-84.